2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Arbutus Biopharma announced plans for a modified Dutch auction tender offer to buy back up to $230 million of its common shares, at $5.00 to $5.75 per share, funded from cash on hand. The offer has not yet commenced and is subject to exemptive relief, so its terms and completion are not assured, but it would return proceeds from the Moderna settlement to shareholders.
Offer to repurchase up to $230 million of common shares at not less than $5.00 and not more than $5.75 per share, in cash
Expected to commence on or about August 24, 2026, and expire on or about September 29, 2026, unless extended or terminated
Funded through the company's cash on hand; commencement depends on obtaining exemptive relief under Canadian and US securities laws
Follows the March 2026 Moderna settlement and a July 2026 initial payment under that settlement
Ubiquiti reported fourth-quarter fiscal 2026 revenue of $937.3 million, up 23.5% from a year earlier, with GAAP diluted EPS of $4.70 versus $4.41. The company also declared a $1.00 per share dividend and extended its $500 million stock repurchase program to September 30, 2027.
Q4 fiscal 2026 (ended June 30, 2026) revenue was $937.3 million, up from $759.2 million a year earlier and $788.2 million in the prior quarter.
Non-GAAP diluted EPS was $4.73, versus $3.54 a year earlier; the prior-year GAAP results included a $53.7 million deferred tax benefit.
Gross margin was 45.8%, down from 47.0% in the prior quarter but up from 45.1% a year earlier.
Board declared a $1.00 per share dividend payable September 8, 2026, to holders of record on August 31, 2026; the $500 million buyback now runs through September 30, 2027.
BJ's Wholesale Club reported second-quarter fiscal 2026 net sales of $6.09 billion, up 15.9%, and diluted EPS of $1.36, up from $1.14 a year earlier. The company raised its full-year fiscal 2026 adjusted EPS outlook to $4.60 to $4.80, and Chief Commercial Officer Paul Cichocki is retiring effective August 21, 2026.
Q2 net sales $6.09 billion, up 15.9%; diluted EPS $1.36 versus $1.14 a year earlier
Comparable club sales rose 11.9%, or 3.1% excluding gasoline sales
Fiscal 2026 adjusted EPS outlook raised to $4.60 to $4.80; capital expenditures of approximately $800 million expected
Chief Commercial Officer Paul Cichocki retires effective August 21, 2026, and serves as part-time advisor through October 1, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.